AzTrials
AzTrials

AmlPhase 1NCT04128020

Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia

A Phase 1 study testing Nivolumab and Azacitidine in people with Aml and AML, Adult, run by Sherif Farag.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This is a phase I clinical trial that will define the maximum tolerated dose (MTD) and investigate the feasibility and safety of the combination of nivolumab and azacitidine after reduced-intensity allogeneic PBSC transplantation. Dose escalation will follow a traditional 3+3 design. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Aml, AML, Adult
What is being tested?
Nivolumab and Azacitidine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
No sites listed yet
Study dates
10 Oct 2019to 28 Sep 2020
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Patients must be capable of understanding the investigational nature, potential risks and benefits of the study and provide valid informed consent.
  • Age ≥ 60 years at the time of consent who are deemed candidates (by their transplant physician) for reduced-intensity allogeneic PBSC transplantation. A recent randomized trial in patients aged 18-65 years demonstrated that myeloablative conditioning regimens are associated with improved overall survival in AML (largely due to a reduction in the risk of relapse), but resulted in equivalent survival in patients with MDS.4 However, it is acknowledged that some AML patients between 55-65 years may not tolerate myeloablative regimens due to associated comorbidities. Physicians should take the risks of the disease versus the patient's comorbidities in deciding on the appropriate preparative regimen in a given patient.
  • Patients aged 18-59 years at the time of consent who are judged not to be candidates for myeloablative allogeneic PBSC transplantation by the transplant physician.
  • Karnofsky performance status (KPS) ≥ 70%
  • Patients must have any of the following hematological malignancies at the time of transplantation:
  • Acute myeloid leukemia (AML) in first (CR1) or subsequent complete remission (CR2, CR3 or beyond), as defined by less than 5% blasts in the bone marrow and peripheral blood.
Show all 35Show fewer
  • Myelodysplastic disorder (MDS) of high or very high-risk according to the revised International Prognostic Scoring System (IPSS-R).1
  • Patients with MDS should have the bone marrow and the peripheral blood blast percentage reduced to <10% within at least 45 days of transplantation.
  • The type of cytoreduction therapy used is at the discretion of the treating physician and may include use of hypomethylating drugs but not immune checkpoint inhibitors.
  • Therapy-related MDS (regardless of IPSS score)
  • Patients must receive a reduced-intensity conditioning (RIC) regimen as defined operationally by the National Marrow Donor Program and CIBMTR. RIC regimens are defined as those containing:
  • ≤ 500 cGy total-body irradiation (TBI)
  • ≤9 mg/kg total busulfan dose (PO or IV)
  • ≤140 mg/m2 total melphalan dose
  • ≤10 mg/kg total thiotepa dose
  • Usually includes a purine analogue (fludarabine, cladribine, or pentostatin).
  • Use of fludarabine and cyclophosphamide (up to 200 mg/kg total dose) is also considered RIC.99
  • Patients must have received GVHD prophylaxis with any of the regimens below. Accepted regimens are:
  • Calcineurin inhibitor (tacrolimus or cyclosporine A) plus methotrexate
  • Calcineurin inhibitor plus mycophenolate mofetil
  • Calcineurin inhibitor plus sirolimus
  • Post-transplant cyclophosphamide (PtCy) (in combination with calcineurin inhibitor or sirolimus, plus mycophenolate mofetil)
  • Patients receiving the above regimens should be beginning to taper immunosuppression drugs between days +100 to +120 (in the absence of acute GVHD) with the goal of discontinuing immunosuppression by approximately day +180 as tolerated and according to institutional standards.
  • Stem cell source must be mobilized peripheral blood (i.e., PBSC) and not bone marrow or cord blood.
  • Allogeneic grafts from 6/6 HLA-matched siblings or from 10/10 HLA allele matched volunteer unrelated donors (matched for at least HLA-A, B, C and DRB1 and DQB1 by high resolution typing) are included.
  • Are in complete remission defined as having <5% blasts in the bone marrow with normal karyotype and no extramedullary disease. This should be documented on a bone marrow biopsy performed within 14 days before study registration.
  • Absolute neutrophil count (ANC) >1.5x109/l
  • Platelet count >100x109/l (with no platelet transfusions in past 7 days)
  • Serum creatinine <2.0 mg/dl
  • Serum bilirubin < 2 x upper limit of normal
  • AST and ALT <2.5 x upper limit of normal
  • Non-pregnant and non-nursing.
  • Women are considered of childbearing potential (WOCBP) unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are post-menopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes.
  • Women of childbearing potential must be willing to abstain from heterosexual activity or use an effective method of contraception from the time of informed consent until 5 months after the last dose of study drug.
  • Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving study drug and who are sexually active with WOCBP will be instructed to adhere to contraception from the first dose of study drug until 7 months after the last dose of study drug.

Who cannot join

  • Use of a myeloablative preparative regimen
  • Active central nervous system (CNS) leukemia. Patients with prior CNS leukemia that is now in remission are eligible.
  • Prior allogeneic or autologous stem cell transplantation before current transplant
  • Use of bone marrow or cord blood as stem cell source
  • History of acute GvHD of any grade
  • Use of systemic corticosteroids within 28 days prior to registration (except for use as replacement for adrenal insufficiency).
Show all 10Show fewer
  • Uncontrolled bacterial, viral or fungal infection at time of registration (defined as currently taking medication and progression or persistence of clinical symptoms). Patients with prior infection (e.g., fungal infection) that is resolved but need continuing prophylaxis can be included.
  • HIV infection or disease at time of transplant. Patients with immune dysfunction are at a significantly higher risk of infection from intensive immunosuppressive therapies. Infectious disease testing will be performed according to local practice.
  • Known additional malignancy that is active and/or progressive requiring treatment; exceptions include basal cell or squamous cell skin cancer, in situ cervical or bladder cancer, or other cancer for which the subject has been disease-free for at least three (3) years.
  • Patients who have received a live/attenuated vaccine within 30 days of first expected treatment with nivolumab. However, it is recommended that patients who have received an allogeneic transplant should not receive live/attenuated vaccines within two years after allogeneic transplantation.

About this study

Official title: Phase I Trial of Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia Big Ten Cancer Research Consortium BTCRC-AML18-342

This is a phase I clinical trial that will define the maximum tolerated dose (MTD) and investigate the feasibility and safety of the combination of nivolumab and azacitidine after reduced-intensity allogeneic PBSC transplantation. Dose escalation will follow a traditional 3+3 design. The investigators will first escalate the dose of single agent nivolumab to determine its MTD (if any, at the doses tested), with an expanded cohort at the MTD or highest dose tested. The investigators will then combine escalating azacitidine in combination of with nivolumab at its determined MTD or highest dose tested in earlier cohorts, and expand the highest dose cohort tested with the combination. Patients will be treated according to the dose level cohorts described in the protocol.

Conditions
Aml, AML, Adult
Being tested
Nivolumab, Azacitidine
Medical subject headings
Leukemia, Myeloid, Acute

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04128020
Study groupRoleWhat they receive
NivolumabExperimentalNivolumab: 0.3, 0.5, or 1.0 mg/kg IV, days 1 \& 15
Receives: Drug: Nivolumab
Nivolumab + AzacitidineExperimentalAzacitidine 8,16, 24 mg/m^2, days 1-5 Nivolumab @MTD (1.0 mg/kg or lower), days 8 \& 15
Receives: Drug: Nivolumab; Drug: Azacitidine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum Tolerated Dose (MTD) of nivolumab

    Maximum Tolerated Dose (MTD) of nivolumab

    Measured: 1 cycle (42 Days)

  2. Maximum Tolerated Dose (MTD) of nivolumab and azacitidine

    Maximum Tolerated Dose (MTD) of nivolumab and azacitidine

    Measured: 1 cycle (42 Days)

Secondary outcomes (9)

  1. Number of Subjects with Adverse Events

    Describe grade 3 and 4 hematological and non-hematological toxicity associated with treatment with azacitidine and nivolumab maintenance treatment after allogeneic PBSC transplantation

    Measured: 2 years

  2. Incidence and severity of acute graft-versus-host disease (GvHD)

    The overall cumulative incidence of acute GvHD (grades 2-4 and grades 3-4), with disease relapse or death from any cause other than GvHD as competing risks, will be described separately for those who receive post-transplant-treatment (at least one dose of either or both drugs), and for those treated at the MTD for nivolumab (Part A) and the combination of nivolumab and azacitidine (Part B) (i.e., including the 12 patients treated in each of the expansion cohorts).

    Measured: 5 years

  3. Incidence and severity of chronic GvHD

    The cumulative incidence of chronic GvHD (mild, moderate, and severe as defined in Section 10.2.2.), with disease relapse or death from any cause other than GvHD as competing risks, will be described separately for those who receive post-transplant-treatment (at least one dose of either or both drugs), and for those treated at the MTD for nivolumab (Part A) and the combination of nivolumab and azacitidine (Part B) (i.e., including the 12 patients treated in each of the expansion cohorts).

    Measured: 5 years

  4. Incidence of infectious complications

    The incidence and severity of infectious complications will be described for patients who receive at least one dose of either or both drugs. Summary data including the type of infections and severity occurring in each dose cohort will be tabulated and presented.

    Measured: 5 years

  5. Cumulative incidence of relapse

    The cumulative incidence of relapse will be derived from calculations of the time from the date of transplantation to the date of confirmed relapse with those dying from causes other than relapse/progression of disease as a competing risk, and right censoring for patients alive and without relapse. The cumulative incidence of relapse will be described separately for those who receive at least one dose of either or both drugs, and for those treated at the MTD for nivolumab (Part A) and the combination of nivolumab and azacitidine (Part B) (i.e., including the 12 patients treated in each of the expansion cohorts).

    Measured: 5 years

  6. Cumulative incidence of non-relapse mortality

    he cumulative incidence of non-relapse mortality will be derived from calculations of the time from the date of transplantation to the date of death from any cause other than disease relapse or progression, with relapse a competing risk, and right censoring for patients alive and without relapse. The cumulative incidence of non-relapse mortality will be described separately for those who receive at least one dose of either or both drugs, and for those treated at the MTD for nivolumab (Part A) and the combination of nivolumab and azacitidine (Part B) (i.e., including the 12 patients treated in each of the expansion cohorts).

    Measured: 5 years

  7. 1 year Overall Survival (OS)

    1-year and overall leukemia-free survival (LFS) will be calculated from the date of transplantation until the time of death from any cause or relapse of underlying disease using the Kaplan-Meier method. LFS will be described separately for those who receive at least one dose of either or both drugs, and for those treated at the MTD for nivolumab (Part A) and the combination of nivolumab and azacitidine (Part B) (i.e., including the 12 patients treated in each of the expansion cohorts).

    Measured: 1 year

  8. Overall Survival

    Overall survival (OS) will be calculated from the date of transplantation until the time of death from any cause using the Kaplan-Meier method. OS will be described separately for those who receive at least one dose of either or both drugs, and for those treated at the MTD for nivolumab (Part A) and the combination of nivolumab and azacitidine (Part B) (i.e., including the 12 patients treated in each of the expansion cohorts).

    Measured: 5 years

  9. Leukemia-Free Survival

    1-year and overall leukemia-free survival (LFS) will be calculated from the date of transplantation until the time of death from any cause or relapse of underlying disease using the Kaplan-Meier method. LFS will be described separately for those who receive at least one dose of either or both drugs, and for those treated at the MTD for nivolumab (Part A) and the combination of nivolumab and azacitidine (Part B) (i.e., including the 12 patients treated in each of the expansion cohorts).

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Oct 2019
  2. Study start10 Oct 2019
  3. Primary completion28 Sep 2020
  4. Study completion28 Sep 2020

Why it stopped: Funder withdrew funding after not accruing any subjects after 1 year.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04128020
Sponsor's protocol ID
BTCRC-AML18-342
Status last verified
Oct 2020
First submitted
14 Oct 2019
Last updated
12 Oct 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Nivolumab and Azacitidine in people with Aml and AML, Adult, run by Sherif Farag.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 35 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 12 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum Tolerated Dose (MTD) of nivolumab (time frame: 1 cycle (42 Days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04128020.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Oct 2020.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in